Posted by Michael Wonder on 20 Nov 2023
Apollomics announces the first approval of vebreltinib for MET exon 14 skip non-small-cell lung cancer
16 November 2023 - Compelling clinical data serving as basis of this approval supports continued development of vebreltinib for the rest of world.
Apollomics today announced that its partner in China, Avistone Biotechnology has received conditional approval from the National Medical Products Administration of China for the commercialisation of vebreltinib to treat patients with MET exon 14 skipping non-small-cell lung cancer.
